BioTelemetry (BEAT) Tops Q3 EPS by 2c

BioTelemetry (NASDAQ: BEAT) reported Q3 EPS of $0.13, $0.02 better than the analyst estimate of $0.11. Revenue for the quarter came in at $43.5 million versus the consensus estimate of $46.05 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Independent Bank receives regulatory approval for HCB Financial acquisition
• Schwab's May activity shows margin loans nearly double